GPCR/G protein
All GPCRs share a common seven trans-membrane structure. GPCRs are associated with heterotrimeric G-proteins which are GTP-binding proteins made of alpha, beta, and gamma subunits. When a ligand binds to GPCR, it activates the attached G-protein, the GDP is replaced with GTP. The activated G-protein then dissociates into an alpha and a beta-gamma complex which activates downstream signaling pathways. These intracellular signaling pathways include cAMP/PKA, calcium/NFAT, phospholipase C, protein tyrosine kinases, MAP kinases, PI-3-kinase, nitric oxide/cGMP, Rho, and JAK/STAT.
GPCRs are one of the most important therapeutic targets for various diseases, over 30% of all modern medicinal drugs target this family. Aberrant GPCR functions are involved in pathological conditions such as neurological, immunological and hormonal disorders. A large number of GPCRs have been identified, but whose ligands are not known, are classified as orphan receptors.
- B1070 AHU-377(Sacubitril)Target: neprilysinSummary: Neprilysin inhibitor
- B1425 BML-190Target: CB2 ReceptorsSummary: CB2 receptor ligand
- B1633 CTEP (RO4956371)1 CitationSummary: MGlu5 inhibitor
- B1200 PRX-08066Summary: 5-HT2BR antagonist
- B1466 WZ811Target: CXCRSummary: Competitive CXCR4 antagonist,highly potent
- B1007 AVE 09911 CitationTarget: Angiotensin AT1 ReceptorsSummary: Agonist of angiotensin-(1-7) receptor
- B1213 AVE 0991 sodium saltSummary: Ang-(1-7) receptor Mas agonist
- B1746 Eprosartan MesylateSummary: Angiotensin AT1 receptor antagonists
- B1879 AdipoRonTarget: AdipoR1|AdipoR2Summary: AdipoR1 and AdipoR2 agonist, first orally active
- B2300 TolvaptanSummary: AVP V2-receptor antagonist